These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

327 related articles for article (PubMed ID: 29853467)

  • 1. Cardiac Phenotype of Prehypertrophic Fabry Disease.
    Nordin S; Kozor R; Baig S; Abdel-Gadir A; Medina-Menacho K; Rosmini S; Captur G; Tchan M; Geberhiwot T; Murphy E; Lachmann R; Ramaswami U; Edwards NC; Hughes D; Steeds RP; Moon JC
    Circ Cardiovasc Imaging; 2018 Jun; 11(6):e007168. PubMed ID: 29853467
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Proposed Stages of Myocardial Phenotype Development in Fabry Disease.
    Nordin S; Kozor R; Medina-Menacho K; Abdel-Gadir A; Baig S; Sado DM; Lobascio I; Murphy E; Lachmann RH; Mehta A; Edwards NC; Ramaswami U; Steeds RP; Hughes D; Moon JC
    JACC Cardiovasc Imaging; 2019 Aug; 12(8 Pt 2):1673-1683. PubMed ID: 29778854
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Global longitudinal strain, myocardial storage and hypertrophy in Fabry disease.
    Vijapurapu R; Nordin S; Baig S; Liu B; Rosmini S; Augusto J; Tchan M; Hughes DA; Geberhiwot T; Moon JC; Steeds RP; Kozor R
    Heart; 2019 Mar; 105(6):470-476. PubMed ID: 30282640
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Myocardial Storage, Inflammation, and Cardiac Phenotype in Fabry Disease After One Year of Enzyme Replacement Therapy.
    Nordin S; Kozor R; Vijapurapu R; Augusto JB; Knott KD; Captur G; Treibel TA; Ramaswami U; Tchan M; Geberhiwot T; Steeds RP; Hughes DA; Moon JC
    Circ Cardiovasc Imaging; 2019 Dec; 12(12):e009430. PubMed ID: 31826677
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Loss of base-to-apex circumferential strain gradient assessed by cardiovascular magnetic resonance in Fabry disease: relationship to T1 mapping, late gadolinium enhancement and hypertrophy.
    Mathur S; Dreisbach JG; Karur GR; Iwanochko RM; Morel CF; Wasim S; Nguyen ET; Wintersperger BJ; Hanneman K
    J Cardiovasc Magn Reson; 2019 Aug; 21(1):45. PubMed ID: 31366357
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predictors of Clinical Evolution in Prehypertrophic Fabry Disease.
    Camporeale A; Pieroni M; Pieruzzi F; Lusardi P; Pica S; Spada M; Mignani R; Burlina A; Bandera F; Guazzi M; Graziani F; Crea F; Greiser A; Boveri S; Ambrogi F; Lombardi M
    Circ Cardiovasc Imaging; 2019 Apr; 12(4):e008424. PubMed ID: 30943767
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The myocardial phenotype of Fabry disease pre-hypertrophy and pre-detectable storage.
    Augusto JB; Johner N; Shah D; Nordin S; Knott KD; Rosmini S; Lau C; Alfarih M; Hughes R; Seraphim A; Vijapurapu R; Bhuva A; Lin L; Ojrzyńska N; Geberhiwot T; Captur G; Ramaswami U; Steeds RP; Kozor R; Hughes D; Moon JC; Namdar M
    Eur Heart J Cardiovasc Imaging; 2021 Jun; 22(7):790-799. PubMed ID: 32514567
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Assessment of Cardiac Involvement in Fabry Disease (FD) with Native T1 Mapping.
    Roller FC; Fuest S; Meyer M; Harth S; Gündüz D; Bauer P; Schneider C; Rolfs A; Krombach GA; Tanislav C
    Rofo; 2019 Oct; 191(10):932-939. PubMed ID: 30754056
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reproducibility of native myocardial T1 mapping in the assessment of Fabry disease and its role in early detection of cardiac involvement by cardiovascular magnetic resonance.
    Pica S; Sado DM; Maestrini V; Fontana M; White SK; Treibel T; Captur G; Anderson S; Piechnik SK; Robson MD; Lachmann RH; Murphy E; Mehta A; Hughes D; Kellman P; Elliott PM; Herrey AS; Moon JC
    J Cardiovasc Magn Reson; 2014 Dec; 16(1):99. PubMed ID: 25475749
    [TBL] [Abstract][Full Text] [Related]  

  • 10. T₁ mapping with cardiovascular MRI is highly sensitive for Fabry disease independent of hypertrophy and sex.
    Thompson RB; Chow K; Khan A; Chan A; Shanks M; Paterson I; Oudit GY
    Circ Cardiovasc Imaging; 2013 Sep; 6(5):637-45. PubMed ID: 23922004
    [TBL] [Abstract][Full Text] [Related]  

  • 11. T1 Mapping in Discrimination of Hypertrophic Phenotypes: Hypertensive Heart Disease and Hypertrophic Cardiomyopathy: Findings From the International T1 Multicenter Cardiovascular Magnetic Resonance Study.
    Hinojar R; Varma N; Child N; Goodman B; Jabbour A; Yu CY; Gebker R; Doltra A; Kelle S; Khan S; Rogers T; Arroyo Ucar E; Cummins C; Carr-White G; Nagel E; Puntmann VO
    Circ Cardiovasc Imaging; 2015 Dec; 8(12):. PubMed ID: 26659373
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Myocardial Edema, Myocyte Injury, and Disease Severity in Fabry Disease.
    Augusto JB; Nordin S; Vijapurapu R; Baig S; Bulluck H; Castelletti S; Alfarih M; Knott K; Captur G; Kotecha T; Ramaswami U; Tchan M; Geberhiwot T; Fontana M; Steeds RP; Hughes D; Kozor R; Moon JC
    Circ Cardiovasc Imaging; 2020 Mar; 13(3):e010171. PubMed ID: 32114828
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characterization of Fabry Disease cardiac involvement according to longitudinal strain, cardiometabolic exercise test, and T1 mapping.
    Réant P; Testet E; Reynaud A; Bourque C; Michaud M; Rooryck C; Goizet C; Lacombe D; de-Précigout V; Peyrou J; Cochet H; Lafitte S
    Int J Cardiovasc Imaging; 2020 Jul; 36(7):1333-1342. PubMed ID: 32385539
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Quantitative Myocardial Perfusion in Fabry Disease.
    Knott KD; Augusto JB; Nordin S; Kozor R; Camaioni C; Xue H; Hughes RK; Manisty C; Brown LAE; Kellman P; Ramaswami U; Hughes D; Plein S; Moon JC
    Circ Cardiovasc Imaging; 2019 Jul; 12(7):e008872. PubMed ID: 31269811
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Increased cardiac involvement in Fabry disease using blood-corrected native T1 mapping.
    Nickander J; Cole B; Nordin S; Vijapurapu R; Steeds RP; Moon JC; Kellman P; Ugander M; Kozor R
    Sci Rep; 2023 Mar; 13(1):4420. PubMed ID: 36932097
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification and assessment of Anderson-Fabry disease by cardiovascular magnetic resonance noncontrast myocardial T1 mapping.
    Sado DM; White SK; Piechnik SK; Banypersad SM; Treibel T; Captur G; Fontana M; Maestrini V; Flett AS; Robson MD; Lachmann RH; Murphy E; Mehta A; Hughes D; Neubauer S; Elliott PM; Moon JC
    Circ Cardiovasc Imaging; 2013 May; 6(3):392-8. PubMed ID: 23564562
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comprehensive Cardiovascular Magnetic Resonance Assessment in Patients With Sarcoidosis and Preserved Left Ventricular Ejection Fraction.
    Greulich S; Kitterer D; Latus J; Aguor E; Steubing H; Kaesemann P; Patrascu A; Greiser A; Groeninger S; Mayr A; Braun N; Alscher MD; Sechtem U; Mahrholdt H
    Circ Cardiovasc Imaging; 2016 Nov; 9(11):. PubMed ID: 27903537
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of Myocardial T1 Mapping at 3.0 T to Differentiate Anderson-Fabry Disease from Hypertrophic Cardiomyopathy.
    Karur GR; Robison S; Iwanochko RM; Morel CF; Crean AM; Thavendiranathan P; Nguyen ET; Mathur S; Wasim S; Hanneman K
    Radiology; 2018 Aug; 288(2):398-406. PubMed ID: 29688154
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differentiation between Fabry disease and hypertrophic cardiomyopathy with cardiac T1 mapping.
    Deborde E; Dubourg B; Bejar S; Brehin AC; Normant S; Michelin P; Dacher JN
    Diagn Interv Imaging; 2020 Feb; 101(2):59-67. PubMed ID: 31519470
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Insight into hypertrophied hearts: a cardiovascular magnetic resonance study of papillary muscle mass and T1 mapping.
    Kozor R; Nordin S; Treibel TA; Rosmini S; Castelletti S; Fontana M; Captur G; Baig S; Steeds RP; Hughes D; Manisty C; Grieve SM; Figtree GA; Moon JC
    Eur Heart J Cardiovasc Imaging; 2017 Sep; 18(9):1034-1040. PubMed ID: 27590835
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.